Stockscreener 앱 받기
10.21
1.49%
0.15
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Keros Therapeutics Inc (KROS) Cash Flow - TradingKey
Keros Therapeutics, Inc. Revenue Breakdown – NASDAQ:KROS - TradingView
KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080 - TradingKey
TradingKey - TradingKey
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
Keros TherapeuticsKeith Regnante Resigns As CFO - TradingView
Keros Therapeutics Announces CFO Resignation and Interim Successor - TipRanks
Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head - Stock Titan
Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily
Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3 - scanx.trade
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
Keros Therapeutics (KROS) Holds Steady Near Support LevelUp Down Volume - dars.gov.et
Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan - Stock Titan
BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics - Stock Titan
Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher - simplywall.st
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
KROS Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Progress ContinuesEPS Growth Rate - dars.gov.et
KROS Q1 2026 Earnings: EPS Miss of 15.98% as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - dars.gov.et
Keros Therapeutics | DEFA14A: Others - Moomoo
Form 4 Keros Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Keros Therapeutics (KROS) grants director Anne Prener RSUs and stock options - Stock Titan
Director Anne Prener files Form 3 insider report at Keros Therapeutics (KROS) - Stock Titan
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors - TipRanks
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - dars.gov.et
Behavioral Patterns of KROS and Institutional Flows - Stock Traders Daily
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 3000E Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell Microcap Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value-Defensive Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Defensive Index - marketscreener.com
Keros Therapeutics Inc. (KROS) Stages Strong Rebound, Testing Resistance at $11.54Sign of Strength - dars.gov.et
KROS Forecast — Price Target — Prediction for 2027 - TradingView
Keros Therapeutics appoints Anne Prener to board of directors By Investing.com - Investing.com Nigeria
Enterprise value to EBIT forward of Keros Therapeutics, Inc. – NASDAQ:KROS - TradingView
Price to sales forward of Keros Therapeutics, Inc. – NASDAQ:KROS - TradingView
Keros Therapeutics appoints Anne Prener to board of directors - Investing.com
Keros Therapeutics Appoints Anne Prener to Board - TipRanks
Anne Prener joins Keros Therapeutics (Nasdaq: KROS) board with equity package - Stock Titan
Keros Therapeutics Appoints Anne Prener to its Board of Directors - GlobeNewswire
Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Keros Therapeutics Inc (KROS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com UK
KROS,LBRX Dividends - Finviz
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis - TradingKey
(KROS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Inc (KROS) Institutional Confidence - TradingKey
Keros Therapeutics Inc (KROS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan - Stock Titan
Insider Sell: Charles Newton Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
1.97%
0.83%
자본화:
|
볼륨(24시간):